This research letter examined the risk of severe generalized pustular psoriasis, as it related to delays of spesolimab initiation because of tuberculosis screening delays.

• Hackley M, Thampy D, Waseh S, et al. Increased risk of severe generalized pustular psoriasis due to tuberculosis screening delay for spesolimab initiation. J Am Acad Dermatol. 2024;90(2):408-410. doi:10.1016/j.jaad.2023.09.078

This literature review evaluated vaccine efficacy and safety to generate consensus-based recommendations for adults receiving systemic therapies for psoriasis and/or psoriatic arthritis receiving non-live or live vaccines.

• Chat VS, Ellebrecht CT, Kingston P, et al. Vaccination Recommendations for Adults Receiving Biologics and Oral Therapies for Psoriasis and Psoriatic Arthritis: Delphi Consensus from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. Published online February 6, 2024. doi:10.1016/j.jaad.2023.12.070

This research examined the association between sleep quantity and history of myocardial infarction in patients with psoriasis.

• Spencer RK, Jin JQ, Elhage KG, et al. Association Between Poor Sleep and Myocardial Infarction in Patients with Psoriasis: Findings from a Cross-Sectional Study with the National Psoriasis Foundation. Dermatology and therapy. 2023;13(11):2903-2909. doi:10.1007/s13555-023-01045-4

This cohort analysis describes the characteristics associated with development of multiple biologic failure versus good clinical response to the first biologic.

• Jin JQ, Cronin A, Roberts-Toler C, et al. Sociodemographic and clinical characteristics associated with multiple biologic failure in psoriasis: A 2015-2022 prospective cohort analysis of the CorEvitas psoriasis registry. Journal of the American Academy of Dermatology. 2023. doi:10.1016/j.jaad.2023.06.058

This study aimed to further explore the extent of patient burden when psoriasis affects special locations, such as the scalp, face, hands, feet, or genitalia.

• Blauvelt A, Gondo GC, Bell S, et al. Psoriasis Involving Special Areas is Associated with Worse Quality of Life, Depression, and Limitations in the Ability to Participate in Social Roles and Activities. Journal of psoriasis and psoriatic arthritis. 2023;0(0):24755303231160683. doi:10.1177/24755303231160683

This guidance is meant to provide providers with much needed information related to utilizing telemedicine in patients living with psoriatic disease.

• Pelet Del Toro N, Yahia R, Feldman SR, Van Voorhees A, Green L, Schwartzman S, Siegel E, Cordoro KM, Desai SR, Kircik L, Liao W, Hawkes JE, Weinberg J, Koo J, Wallace EB, Howard LM, Armstrong A, Han G. National Psoriasis Foundation Telemedicine Task Force guidance for management of psoriatic disease via telemedicine. JAAD Int. 2023 Apr 5;12:32-36. doi: 10.1016/j.jdin.2023.02.018. PMID:37274387; PMCID: PMC10238745.

With the increasing availability of biosimilars in the USA market, the Medical Board felt it was important to share their updated position on use in patients with psoriasis and psoriatic arthritis.

• Armstrong A, Callis-Duffin K, Feldman S, Glick B, Kalb R, Reddy S, Schwartzman S, Yamauchi P, Calabrese C, Cordoro K, Desai S, Gladman D, Han G, Hawkes JE, Hsu S, Kircik L, Koo J, Kreuger GG, Lebwohl M, Leonardi C, Lewitt GM, Liao W, Liu C, Markenson J, Merola JF, Orbai A, Prussick R, Richardson V, Soung J, Van Voorhees AS, Wallace E, Weinberg J, Wine Lee L, Harris J, Koons S, Howard L. Position Statement on the Use of Biosimilars for Psoriasis and Psoriatic Arthritis. National Psoriasis Foundation. 2023. https://www.psoriasis.org/position-statement-on-biosimilars/

As medical cannabis becomes more widely available, the NPF Medical Board was surveyed to provide their perceptions and experience with it.

• Nussbaum D, Desai S, Gonzalez-Lopez A, Hawkes JE, Gondo G, Friedman A. Practices and perspectives on medical cannabis and cannabinoids: A Survey of the National Psoriasis Foundation Medical Advisory Board. JAAD International. 2022. https://doi.org/10.1016/j.jdin.2022.07.001.

The NPF Medical Board provides their expert opinion on non-medical switching of treatments.

• Armstrong A, Lebwohl M, Merola JF, Koons S, Fried R, Hawkes J, et al. Non-Medical Switching Impact on Patients and Providers – Psoriatic Disease Community Taking a Stand. Journal of Psoriasis and Psoriatic Arthritis. 2021:24755303211024205 https://doi.org/10.1177/24755303211024205.

This review provides insights in the pathogenesis of psoriatic disease and precision medicine treatment approach.

• Yan D, Gudjonsson JE, Le S, Maverakis E, Plazyo O, Ritchlin C, et al. New Frontiers in Psoriatic Disease Research, Part I: Genetics, Environmental Triggers, Immunology, Pathophysiology, and Precision Medicine. Journal of Investigative Dermatology. 2021;141(9):2112-22.e3 https://dx.doi.org/10.1016/j.jid.2021.02.764.

This review discusses comorbidities associated with psoriatic disease as well as treatment advances.

• Yan D, Blauvelt A, Dey AK, Golpanian RS, Hwang ST, Mehta NN, et al. New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies. Journal of Investigative Dermatology. 2021;141(10):2328-37 https://dx.doi.org/10.1016/j.jid.2021.02.743.

This survey of the NPF Medical Board sought to better understand psoriasis of the ear and current approaches for management.

• Blake A, Enos C, Armstrong AW, et al. Results of a Survey of the National Psoriasis Foundation Medical Board on the Management of Ear Psoriasis. Journal of Psoriasis and Psoriatic Arthritis. 2020;5(1):28-31. doi:10.1177/2475530319891954

This cohort research examines the applicability of the NPF treat-to-target guidelines for psoriasis in clinical practice.

• Merola JF, Perez Chada LM, Siegel M, Bagel J, Evans C, Lockshin B, et al. The National Psoriasis Foundation psoriasis treatment targets in real-world patients: prevalence and association with patient-reported outcomes in the Corrona Psoriasis Registry. Journal of the European Academy of Dermatology and Venereology. 2020;34(9):2051-8 https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.16274.

This review examines the relationship between psoriasis and hypertension and provides practical screening and treatment recommendations for dermatologists to address hypertension in patients with psoriasis.

• deShazo RA, Secrest AM, Armstrong AW, Duffin KC. Addressing Hypertension in Patients With Psoriasis: Review and Recommendations.Journal of Psoriasis and Psoriatic Arthritis. 2020;5(4):129-138. doi:10.1177/2475530320936373

This review assesses herpes zoster (HZ) risk in patients with psoriasis and PsA by systemic treatment and provide recommendations regarding HZ vaccination.

• Baumrin E, Van Voorhees A, Garg A, Feldman SR, Merola JF. A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology. 2019;81(1):102-10 https://pubmed.ncbi.nlm.nih.gov/30885757/.

This review provides evidence-based dietary recommendations for adults with psoriasis and/or psoriatic arthritis from the Medical Board of the National Psoriasis Foundation.

• Ford AR, Siegel M, Bagel J, Cordoro KM, Garg A, Gottlieb A, et al. Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic Review. JAMA Dermatology. 2018;154(8):934-50 https://pubmed.ncbi.nlm.nih.gov/29926091/.

This review provides best practice recommendations for organ transplant recipients diagnosed with psoriasis vulgaris.

• Prussick R, Wu JJ, Armstrong AW, Siegel MP, Van Voorhees AS. Psoriasis in solid organ transplant patients: best practice recommendations from The Medical Board of the National Psoriasis Foundation. The Journal of Dermatological Treatment. 2018;29(4):329-33 https://pubmed.ncbi.nlm.nih.gov/28884635/.

This review examines therapeutic options for patients with psoriasis and concurrent inflammatory bowel disease.

• Whitlock SM, Enos CW, Armstrong AW, Gottlieb A, Langley RG, Lebwohl M, et al. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology. 2018;78(2):383-94 https://pubmed.ncbi.nlm.nih.gov/29332708/.

This review provides updated consensus on treating inverse/intertriginous psoriasis.

• Khosravi H, Siegel MP, Van Voorhees AS, Merola JF. Treatment of Inverse/Intertriginous Psoriasis: Updated Guidelines from the Medical Board of the National Psoriasis Foundation. Journal of Drugs in Dermatology: JDD. 2017;16(8):760-6 https://pubmed.ncbi.nlm.nih.gov/28809991/.

This review examined the perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis and provided clinical guidance.

• Choi YM, Debbaneh M, Weinberg JM, Yamauchi PS, Van Voorhees AS, Armstrong AW, et al. From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis. Journal of the American Academy of Dermatology. 2016;75(4):798-805.e7 https://pubmed.ncbi.nlm.nih.gov/27461230/.

This review offers evidence-based, best-practice recommendations regarding combining biologics with other systemic treatments.

• Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation. JAMA Dermatology. 2015;151(4):432-8 https://pubmed.ncbi.nlm.nih.gov/25517130/.

This review provides best practice recommendations for treating nail psoriasis.

• Crowley JJ, Weinberg JM, Wu JJ, Robertson AD, Van Voorhees AS. Treatment of nail psoriasis: best practice recommendations from the Medical Board of the National Psoriasis Foundation. JAMA Dermatology. 2015;151(1):87-94 https://pubmed.ncbi.nlm.nih.gov/25471223/.

This review examines the impact of common psoriasis therapies on cardiovascular measures and outcomes.

• Hugh J, Van Voorhees AS, Nijhawan RI, Bagel J, Lebwohl M, Blauvelt A, et al. From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. Journal of the American Academy of Dermatology. 2014;70(1):168-77 https://pubmed.ncbi.nlm.nih.gov/24184141/.

This review provides recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis.

• Motaparthi K, Stanisic V, Van Voorhees AS, Lebwohl MG, Hsu S. From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis. Journal of the American Academy of Dermatology. 2014;70(1):178-86 https://pubmed.ncbi.nlm.nih.gov/24220724/.

This review examined literature regarding vaccine-preventable illness and vaccinations commonly used in the United States in patients older than 18 years on immunosuppressive therapies that are used in the treatment of psoriasis.

• Wine-Lee L, Keller SC, Wilck MB, Gluckman SJ, Van Voorhees AS. From the Medical Board of the National Psoriasis Foundation: Vaccination in adult patients on systemic therapy for psoriasis. Journal of the American Academy of Dermatology. 2013;69(6):1003-13 https://pubmed.ncbi.nlm.nih.gov/24075223/.

This review provides consensus recommendations on treatment options for psoriasis in pregnant and lactating women.

• Bae YS, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Young M, et al. Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology. 2012;67(3):459-77 https://pubmed.ncbi.nlm.nih.gov/22018758/.

This review presents treatment recommendations to aid in the treatment of patients with pustular psoriasis.

• Robinson A, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Bebo BF, Jr., et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology. 2012;67(2):279-88. https://pubmed.ncbi.nlm.nih.gov/22609220/.

This review presents a treatment algorithm for patients with psoriasis who are older than 65 years.

• Grozdev IS, Van Voorhees AS, Gottlieb AB, Hsu S, Lebwohl MG, Bebo BF, Jr., et al. Psoriasis in the elderly: from the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology. 2011;65(3):537-45 https://pubmed.ncbi.nlm.nih.gov/21496950/.

This review provides information related to obesity and psoriasis.

• Bremmer S, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Young M, et al. Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology. 2010;63(6):1058-69 https://pubmed.ncbi.nlm.nih.gov/20692722/.

A task force of the NPF Medical Board completed a review to evaluate treatment options for patients living with psoriasis and HIV infection.

• Menon K, Van Voorhees AS, Bebo BF, Jr., Gladman DD, Hsu S, Kalb RE, et al. Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology. 2010;62(2):291-9 https://pubmed.ncbi.nlm.nih.gov/19646777/.

A task force of the NPF Medical Board completed a review to evaluate treatment options for erythrodermic or exfoliative psoriasis.

• Rosenbach M, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo BF, Jr., et al. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology. 2010;62(4):655-62 https://pubmed.ncbi.nlm.nih.gov/19665821/.

A task force of the NPF Medical Board completed a review to evaluate treatment options for severe scalp psoriasis.

• Chan CS, Van Voorhees AS, Lebwohl MG, Korman NJ, Young M, Bebo BF, Jr., et al. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology. 2009;60(6):962-71 https://pubmed.ncbi.nlm.nih.gov/19375191/.

This review aims to provide a consensus statement on treating psoriasis in patients with concomitant HCV infection.

• Frankel AJ, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Bebo BF, Jr., et al. Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology. 2009;61(6):1044-55 https://pubmed.ncbi.nlm.nih.gov/19811848/.

A task force of the NPF Medical Board completed a review to evaluate treatment options for intertriginous or inverse psoriasis.

• Kalb RE, Bagel J, Korman NJ, Lebwohl MG, Young M, Horn EJ, et al. Treatment of intertriginous psoriasis: from the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology. 2009;60(1):120-4 https://pubmed.ncbi.nlm.nih.gov/19103363/.

This review aims to provide a consensus statement on the kind of monitoring and vaccinations that should be performed before and during biologic therapy in patients with psoriasis.

• Lebwohl M, Bagel J, Gelfand JM, Gladman D, Gordon KB, Hsu S, et al. From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. Journal of the American Academy of Dermatology. 2008;58(1):94-105 https://pubmed.ncbi.nlm.nih.gov/17980456/.

Barbieri JS, Beidas RS, Gondo GC, Fishman J, Williams NJ, Armstrong AW, et al. Analysis of Specialist and Patient Perspectives on Strategies to Improve Cardiovascular Disease Prevention Among Persons With Psoriatic Disease. JAMA Dermatology. 2022 https://dx.doi.org/10.1001/jamadermatol.2021.4467.

Gondo G, Hadeler E, Brownstone N, Maverakis E, Merola J, Armstrong A, et al. Demographic and Clinical Factors Associated with Patient-Reported Remission in Psoriasis. Dermatology and Therapy. 2022 https://doi.org/10.1007/s13555-022-00692-3.

Gondo G, Mosca M, Hong J, Maverakis E, Merola JF, Armstrong AW, et al. Demographic and Clinical Factors Associated with Patient-Reported Remission in Psoriatic Arthritis. Dermatology and Therapy. 2022 https://doi.org/10.1007/s13555-022-00770-6.

Gondo G, Howard L, Friesel R, Gottlieb AB, Merola J. 257 Understanding health disparities among patients with psoriasis: Results from National Psoriasis Foundation annual surveys 2019 - 2021. Journal of Investigative Dermatology. 2022;142(8):S43 https://doi.org/10.1016/j.jid.2022.05.264.

Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, et al. National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 2 - Advances in Psoriatic Disease Management, COVID-19 Vaccines, and COVID-19 Treatments. Journal of the American Academy of Dermatology. 2021 https://pubmed.ncbi.nlm.nih.gov/33422626/.

Gondo GC, Merola JF, Bell S, Blauvelt A. Decreased quality of life in people with psoriasis and psoriatic arthritis versus people with psoriasis alone: data from a national US survey. The British journal of Dermatology. 2021. https://pubmed.ncbi.nlm.nih.gov/34289088/.

Gondo GC, Koons S, Metcalf C, Bell SJ, Mehta NN. Viewing Psoriasis as a Systemic Disease for Better Health Outcomes. JID Innovations. 2021:100007 https://www.sciencedirect.com/science/article/pii/S2667026721000072.

Gondo GC, Bell SJ, Slayden J, Ullmann G, Blauvelt A. Concerns and perceptions of patients with psoriatic disease during the COVID-19 pandemic: results from a two-wave survey by the National Psoriasis Foundation. Journal of the European Academy of Dermatology and Venereology. 2021;35(6):e354-e5 https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.17173.

Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis Prevalence in Adults in the United States. JAMA dermatology. 2021 https://doi.org/10.1001/jamadermatol.2021.2007.

Armstrong AW, Archuleta L, Gutierrez Y, Liao W, Bell SJ, Gondo G. Validation of Patient-Reported Psoriasis Diagnosis from a Global Online Research Network. Journal of Investigative Dermatology. 2021 https://doi.org/10.1016/j.jid.2021.03.021.

Gondo G, Heydon S, Bell S. Perspective of psoriatic disease patients on novel COVID-19 vaccines. Journal of Investigative Dermatology. 2021;141(5):S66 https://doi.org/10.1016/j.jid.2021.02.403.

Gondo G, Bell S, Merola J, Gottlieb A. Differences in musculoskeletal impact on health among patients with psoriasis based on disease type, disease severity and undiagnosed psoriatic arthritis (PsA). Journal of Investigative Dermatology. 2021;141(5):S67 https://doi.org/10.1016/j.jid.2021.02.406.

Gondo G, Hadeler E, Brownstone N, Maverakis E, Merola J, Armstrong A, et al. Demographic and clinical factors associated with patient-reported remission in psoriasis. Journal of Investigative Dermatology. 2021;141(5):S71 https://doi.org/10.1016/j.jid.2021.02.434.

Gondo G, Mosca M, Hong J, Maverakis E, Armstrong A, Merola J, et al. Demographic and clinical factors associated with patient-reported remission in psoriatic arthritis. Journal of Investigative Dermatology. 2021;141(5):S51 https://doi.org/10.1016/j.jid.2021.02.313.

Gondo GC, Noe MH, Bell SJ, Ritchlin CT. Likelihood of COVID-19 Vaccination Among Individuals Living With Psoriatic Disease: Results From a Large Real-World Survey. Journal of Psoriasis and Psoriatic Arthritis. 2021;7(1):17-23 https://doi.org/10.1177/24755303211067822.

Balak DMW, Perez-Chada LM, Guo LN, Mita C, Armstrong AW, Bell SJ, et al. Defining Psoriasis Remission Based on Histopathologic and Molecular Criteria: A Systematic Literature Review. The Journal of Investigative Dermatology. 2021 https://doi.org/10.1016/j.jid.2021.09.039.

Enos CW, Galadima H, Saini AD, Bell S, Siegel M, Van Voorhees AS. Predictors of Biologic Use and Satisfaction Among Patients With Psoriasis: An Analysis and Geographic Visualization of the 2016 and 2017 National Psoriasis Foundation Annual Surveys. Journal of Psoriasis and Psoriatic Arthritis. 2020;5(3):100-8 https://journals.sagepub.com/doi/abs/10.1177/2475530320925553.

Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, et al. National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. Journal of the American Academy of Dermatology. 2020;83(6):1704-16 https://www.ncbi.nlm.nih.gov/pubmed/32891785..

Gondo G, Boles J, Stone P, Howard L, Bell SJ. Prevalence of Utilization Management Policies Among the Psoriatic Disease Community: Results From the 2019 National Psoriasis Foundation Advocacy Survey. Journal of Psoriasis and Psoriatic Arthritis. 2020;5(04):2475530320956602 https://journals.sagepub.com/doi/abs/10.1177/2475530320956602.

Gondo G, Domire J, Merola JF, Gottlieb A, Bell S. Understanding the impact of psoriatic disease on mental health: Results from the National Psoriasis Foundation Annual Survey. Journal of Investigative Dermatology. 2020;140(7):S61 https://doi.org/10.1016/j.jid.2020.03.467.

Merola JF, Gondo G, Bell S, Callis Duffin K, Gottlieb A. Understanding the prevalence of potentially undiagnosed psoriatic arthritis and the impact on patient quality of life: Results from the National Psoriasis Foundation's Annual Survey.  29th Annual Congress of the European Academy of Dermatology and Venerology; Vienna, Austria 2020.

Bell S, Merola JF, Webster DE, Pennington SR, Liao W, Ogdie A, et al. Aiming for Cure and Preventive Initiatives in Psoriatic Disease: Building Synergy at NPF, GRAPPA, and PPACMAN. Curr Rheumatol Rep. 2020;22(11):78 https://pubmed.ncbi.nlm.nih.gov/32959152/.

Bell S, Nahle Z, Adamopoulos IE. Psoriatic arthritis; overcoming the challenges by creating opportunities. Clin Immunol. 2020;218:108519 https://pubmed.ncbi.nlm.nih.gov/32621978/.

Bell S, Domire J, Merola JF, Gottlieb A, Gondo G. The impact of psoriasis and its associated comorbidities on quality of life: Results from the National Psoriasis Foundation Annual Survey. Journal of Investigative Dermatology. 2020;140(7):S67 https://doi.org/10.1016/j.jid.2020.03.504.

Smith MP, Ly K, Thibodeaux Q, Weerasinghe T, Beck K, Shankle L, et al. Factors Influencing Sleep Difficulty and Sleep Quantity in the Citizen Pscientist Psoriatic Cohort. Dermatology and Therapy. 2019;9(3):511-23 https://www.ncbi.nlm.nih.gov/pubmed/31177381.

Teeple A, Ellis LA, Huff L, Reynolds C, Ginsburg S, Howard L, et al. Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States. Curr Med Res Opin. 2019;35(4):611-7 https://pubmed.ncbi.nlm.nih.gov/30712393/. 

Teeple A, Ginsburg S, Howard L, Huff L, Reynolds C, Walls D, et al. Patient attitudes about non-medical switching to biosimilars: results from an online patient survey in the United States. Curr Med Res Opin. 2019;35(4):603-9 https://pubmed.ncbi.nlm.nih.gov/30618353/.  

Albrecht J, Lebwohl M, Asgari MM, Bennett DD, Cook A, Evans CC, et al. The state and consequences of dermatology drug prices in the United States. Journal of the American Academy of Dermatology. 2016;75(3):603-5 https://www.ncbi.nlm.nih.gov/pubmed/27423978.

McCormick Howard L. National Psoriasis Foundation: a patient-centric approach to improve access to psoriatic disease treatment. Am J Manag Care. 2016;22(4 Suppl):s104-7 https://pubmed.ncbi.nlm.nih.gov/27270154/.

Duffin KC, Yeung H, Takeshita J, Krueger GG, Robertson AD, Troxel AB, et al. Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice. The British Journal of Dermatology. 2014;170(3):672-80 https://pubmed.ncbi.nlm.nih.gov/24266717/.

Takeshita J, Callis Duffin K, Shin DB, Krueger GG, Robertson AD, Troxel AB, et al. Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting. Journal of the American Academy of Dermatology. 2014;71(4):633-41 https://www.ncbi.nlm.nih.gov/pubmed/24928705.

Abuabara K, Wan J, Troxel AB, Shin DB, Van Voorhees AS, Bebo BF, Jr., et al. Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis. Journal of the American Academy of Dermatology. 2013;68(2):262-9 https://www.ncbi.nlm.nih.gov/pubmed/22910105.

Bhutani T, Wong JW, Bebo BF, Armstrong AW. Access to health care in patients with psoriasis and psoriatic arthritis: data from National Psoriasis Foundation survey panels. JAMA Dermatology. 2013;149(6):717-21 https://pubmed.ncbi.nlm.nih.gov/23783152/.

Helmick CG, Sacks JJ, Gelfand JM, Bebo B, Jr., Lee-Han H, Baird T, et al. Psoriasis and psoriatic arthritis: a public health agenda. American Journal of Preventive Medicine. 2013;44(4):424-6 https://www.ncbi.nlm.nih.gov/pubmed/23498110.

Yeung H, Wan J, Van Voorhees AS, Callis Duffin K, Krueger GG, Kalb RE, et al. Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. Journal of the American Academy of Dermatology. 2013;68(1):64-72 https://www.ncbi.nlm.nih.gov/pubmed/22846688.

Armstrong AW, Schupp C, Bebo B. Psoriasis Comorbidities: Results from the National Psoriasis Foundation Surveys 2003 to 2011. Dermatology. 2012;225(2):121-6 https://pubmed.ncbi.nlm.nih.gov/23108113/.

Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011. PLoS One. 2012;7(12):e52935 https://www.ncbi.nlm.nih.gov/pubmed/23285231.

Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, et al. Epidemiology of psoriatic arthritis in the population of the United States. Journal of the American Academy of Dermatology. 2005;53(4):573 https://pubmed.ncbi.nlm.nih.gov/16198775/.

Gelfand JM, Stern RS, Nijsten T, Feldman SR, Thomas J, Kist J, et al. The prevalence of psoriasis in African Americans: results from a population-based study. Journal of the American Academy of Dermatology. 2005;52(1):23-6. https://pubmed.ncbi.nlm.nih.gov/15627076/.

Nijsten T, Margolis DJ, Feldman SR, Rolstad T, Stern RS. Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. Journal of the American Academy of Dermatology. 2005;52(3 Pt 1):434-44 https://www.ncbi.nlm.nih.gov/pubmed/15761421.

Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinants of quality of life in patients with psoriasis: a study from the US population. Journal of the American Academy of Dermatology. 2004;51(5):704-8 https://pubmed.ncbi.nlm.nih.gov/15523347/.

Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9(2):136-9 https://pubmed.ncbi.nlm.nih.gov/15083780/.

Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Archives of Dermatology. 2001;137(3):280-4 https://pubmed.ncbi.nlm.nih.gov/11255325/.

Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. Journal of the American Academy of Dermatology. 2020 https://www.ncbi.nlm.nih.gov/pubmed/32738429.

Menter A, Gelfand JM, Connor C, Armstrong AW, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. Journal of the American Academy of Dermatology. 2020;82(6):1445-86 https://www.ncbi.nlm.nih.gov/pubmed/32119894.

Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. Journal of the American Academy of Dermatology. 2019;80(4):1073-113 https://doi.org/10.1016/j.jaad.2018.11.058.

Elmets CA, Lim HW, Stoff B, Connaor C, Cordoro KM, Lebwohl M, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. Journal of the American Academy of Dermatology. 2019;81(3):775-804 https://www.ncbi.nlm.nih.gov/pubmed/31351884.

Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. Journal of the American Academy of Dermatology. 2019;80(4):1029-72 https://www.ncbi.nlm.nih.gov/pubmed/30772098.

Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Care & Research. 2019;71(1):2-29 https://onlinelibrary.wiley.com/doi/abs/10.1002/acr.23789.